About this trial
Left ventricular assist device (LVAD) candidates will be comprehensively evaluated at our center, including clinical evaluation, echocardiography, right heart catheterization, cardiopulmonary exercise test and laboratory exams. following this evaluation, patients will be treated with inotropes, diuretics, uptitrated neurohormonal therapy. vitamin and iron deficiencies will be corrected and the patients will be referred for coronary interventions and cardiac resynchronization therapy appropriately. The need for LVAD implantation will be reevaluated according to the patient's clinical condition, echocardiography and laboratory findings.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Advanced symptomatic heart failure patients with reduced ejection fraction in whom a left ventricular assist device implantation is planned.
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
New York Heart Association (NYHA) Class
improvement in NYHA class
Secondary outcomes
Maximal oxygen consumption (VO2)
improvement in VO2
natriuretic peptide levels
reduction in brain natriuretic peptide levels
left ventricular size
reduction in left ventricular end diastolic diameter
Sponsors and contacts
Click on the lead sponsor to view all of their trials.